Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 299 people in the ZD4054 group and 295 people in the placebo (dummy treatment) group — a total of 594 participants. The trial was studying men with a form of advanced prostate cancer that had spread to the bones, and it was primarily measuring how long participants lived overall. It also tracked a number of secondary measurements, including how long before the cancer visibly grew, how long before stronger pain medicines (opiates) were needed, how long before bone-related complications occurred, how long before new bone lesions appeared, and how long before quality of life declined. The reported data shows that, for the main measurement — overall survival — the median time from joining the trial until death was 24.5 months in the ZD4054 group and 22.5 months in the placebo group. (Median means half the participants in each group had this outcome before that time, and half after.) For the secondary measurements, the reported data shows: the median time before the cancer showed signs of growing was 6.2 months (ZD4054) versus 6.5 months (placebo); the median time before opiate pain medicines were used was 16.7 months (ZD4054) versus 14.8 months (placebo); the median time before a bone-related complication occurred was 18.4 months (ZD4054) versus 17.1 months (placebo); the median time before four or more new bone lesions appeared was 15.1 months (ZD4054) versus 11.9 months (placebo); and the median time before a meaningful decline in quality of life was recorded was 5.5 months in both groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Prostate Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with prostate cancer that has spread to the bones
- Your PSA (a protein measured in a blood test related to prostate cancer) has been rising over the past month
- You have no pain, or only mild pain, caused by your prostate cancer
- You are currently having treatment to lower testosterone levels, either through surgery or medication
Who may not be able to join:
- You are currently taking strong (opiate-based) painkillers, such as morphine or codeine
- You have previously had chemotherapy with paclitaxel, docetaxel, or mitoxantrone
- You have heart failure, or you have had a heart attack in the last 6 months
- You have a history of epilepsy or seizures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Martin Gleave, MD, FRCSC, FACS, The Prostate Centre at Vancouver General Hospital
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.